eMedicine Specialties > Emergency Medicine > Pediatric

Pediatrics, Pertussis

Author: Joseph J Bocka, MD, Director of Shelby Emergency Department, Attending Emergency Physician at Mansfield Hospital, Med Central Health System (Mansfield and Shelby, Ohio); Emergency Medical Service Medical Director for several services
Contributor Information and Disclosures

Updated: May 26, 2009

Introduction

Background

In the prevaccination era, pertussis (ie, whooping cough) was a leading cause of infant death. The number of cases reported had decreased by more than 99% from the 1930s to the 1980s. However, because of many local outbreaks, the number cases reported in the United States increased by more than 2300% between 1976 and 2005, when the recent peak of 25,616 cases were reported.1 The disease is still a significant cause of morbidity and mortality in infants younger than 2 years. Pertussis should be included in the differential diagnosis of protracted cough with cyanosis or vomiting, persistent rhinorrhea, and marked lymphocytosis.

Pathophysiology

Bordetella pertussis is an aerobic, nonmotile, gram-negative coccobacillus that attaches to and multiplies on the respiratory epithelium, starting in the nasopharynx and ending primarily in the bronchi and bronchioles. Transmission is only human to human by means of exposure to aerosol droplets. The disease is highly contagious. Approximately 80-90% of susceptible individuals who are exposed develop the disease. Most cases occur in the late summer and early fall.

A mucopurulosanguineous exudate forms in the respiratory tract. This exudate compromises the small airways (especially those of infants) and predisposes the affected individual to atelectasis, cough, cyanosis, and pneumonia. The lung parenchyma and bloodstream are not invaded; therefore, blood culture results are negative.

Frequency

United States

The rate of pertussis peaked in the 1930s, with 265,269 cases and 7518 deaths reported in the United States. This rate decreased to a low in 1976, when 1010 cases and 4 deaths occurred. The rate recently peaked to 25,616 cases (8.7 cases per 100,000 people per year) reported to the Centers for Disease Control and Prevention (CDC) in 2005 and 15,632 (5.2 per 100,000) reported in 2006. The CDC estimates that 5-10% of all cases of pertussis are recognized and reported. Pertussis remains the most commonly reported vaccine-preventable disease in the United States in children younger than 5 years.

In reported studies, 12-32% of adults with prolonged (1-4 wk) cough have pertussis.

International

In England, the percentage of people vaccinated over the last 4 decades decreased to less than 30%. This decline has resulted in thousands of cases reported recently, a rate that approaches the incidence in the prevaccination era. Similar epidemic outbreaks have recently occurred in Sweden, Canada, and Germany. Nearly 300,000 deaths from pertussis in Africa are thought to have occurred over the last decade.

Mortality/Morbidity

The mortality rate had been greater than 50%. Now, the mortality rate for hospitalized patients in the United States and in Europe is about 1 per 500 cases (<0.2% of those reported). The overall infant mortality rate is 2.4 per 1 million live births. The CDC reported 39 deaths from pertussis in 2005; 32 (82%) occurred in infants younger than 3 months. The World Health Organization (WHO) estimates that 294,000 children died from pertussis worldwide in 2002.

  • About 90-95% of patients die from secondary pneumonia, dehydration, hypoxia, encephalopathy, or cerebral hemorrhage. Cerebral hemorrhage occurs secondary to paroxysmal coughing, which elevates the intracranial pressure (ICP).
  • Today, about 10-25% of children younger than 4 years and 2-4% of all persons with pertussis secondarily develop bacterial pneumonia. Approximately 1-2% of infants and 0.3-0.6% of adults develop seizures, which are believed to be a result of hypoxia or cerebral hemorrhage from the prolonged coughing spells. About 0.1% develop encephalopathy.
  • In the prevaccination era, pertussis caused more than 270,000 cases and nearly 10,000 deaths annually. This rate reached a low of 4 reported deaths in the United States in 1982 and has recently risen to an average of about 25 deaths annually, with 39 being reported in 2005.

Sex

Pertussis is more common in girls than in boys.

Age

  • Pertussis occurs predominantly in those aged 3 months to 5 years, with more than 70% of cases reported in children younger than 5 years.
  • Because of the lack of maternal immunity transfer, 10-15 % of all cases occur in infants younger than 6 months, yet more than 90% of all deaths occur in this same age group. However, the growing majority of cases are now in those aged 10 years and older, which has led to increased booster recommendations.
  • The natural disease does not provide lifelong immunity as earlier thought. Three injections of the cellular or acellular vaccine provide up to 12 years of protection. These vaccinations help account for the more than 10-fold increase reported in those older than 18 years.

Clinical

History

  • Pertussis typically consists of 3 stages: incubation, catarrhal, and paroxysmal.
  • The asymptomatic incubation period lasts 7-10 days.
  • The catarrhal stage follows and lasts about 2-7 days. Findings include the following:
    • Minimal or no fever
    • Rhinorrhea
    • Anorexia
    • Mild but increasing cough
  • The paroxysmal stage follows, lasting about 1-8 weeks.
    • It is characterized by paroxysms of coughing, which are provoked by feeding (in infants) and exertion.
    • These paroxysms are less spontaneous than those observed in typical respiratory infections.
    • The inspiratory gasp or whoop eventually develops, especially in those aged 6 months to 5 years.
  • Infants younger than 6 months often have vomiting in association with the cough, which leads to dehydration.
    • Hypoxia tends to be more severe than what the child's clinical appearance suggests.
    • A substantial number of patients present with cyanosis and apneic spells.
  • Vaccinated adults usually develop only prolonged bronchitis without a whoop, whereas unvaccinated adults are most likely to have whooping and posttussive emesis.
  • About 12-32% of adults with persistent cough (>2 wk) have pertussis. On average, they wait a median of 3 weeks before seeking treatment.

Physical

  • The classic inspiratory gasp or whoop primarily develops in those aged 6 months to 5 years. It is usually absent in those younger than 6 months and in most older vaccinated children and adults; however, it can often be observed in unvaccinated adults, as can posttussive emesis.
  • Hypoxia should be considered and assessed.
  • Dehydration is common on presentation.
  • Mild fever is common. Fever with a temperature of over 39°C is rare.

Causes

  • The main causative organism is B pertussis.
  • Bordetella parapertussis and Bordetella bronchiseptica are less common than B pertussis and produce a clinical illness that is similar but milder to pertussis due to B pertussis.
  • Risk factors include the following:
    • Nonvaccination in children
    • Contact with an infected person
    • Epidemic exposure
    • Pregnancy

More on Pediatrics, Pertussis

Overview: Pediatrics, Pertussis
Differential Diagnoses & Workup: Pediatrics, Pertussis
Treatment & Medication: Pediatrics, Pertussis
Follow-up: Pediatrics, Pertussis
References
Further Reading

References

  1. Centers for Disease Control and Prevention. Outbreaks of respiratory illness mistakenly attributed to pertussis--New Hampshire, Massachusetts, and Tennessee, 2004-2006. MMWR Morb Mortal Wkly Rep. Aug 24 2007;56(33):837-42. [Medline][Full Text].

  2. Glanz JM, McClure DL, Magid DJ, Daley MF, France EK, Salmon DA, et al. Parental refusal of pertussis vaccination is associated with an increased risk of pertussis infection in children. Pediatrics. June 2009;123(6):1446-51. [Full Text].

  3. Centers for Disease Control and Prevention. Immunization Schedules. Available at http://www.cdc.gov/vaccines/recs/schedules/default.htm. Accessed March 31, 2009.

  4. [Guideline] Recommended childhood and adolescent immunization schedules--United States, 2009. Pediatrics. Jan 2009;123(1):189-90. [Medline].

  5. [Guideline] Centers for Disease Control and Prevention. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five-dose series. (Addendum). 1997 guideline with 2000-2003 supplements. [Full Text].

  6. [Guideline] American Academy of Pediatrics Commitee on Infectious Diseases. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. Pediatrics. Mar 2006;117(3):965-78. [Medline].

  7. Aoyama T, Sunakawa K, Iwata S, et al. Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin. J Pediatr. Nov 1996;129(5):761-4. [Medline].

  8. Bass JW, Stephenson SR. The return of pertussis. Pediatr Infect Dis J. Feb 1987;6(2):141-4. [Medline].

  9. Centers for Disease Control and Prevention. Recommended Adult Immunization Schedule-United States, October 2007-September 2008. MMWR Morb Mortal Wkly Rep. Oct 19 2007;56(41):Q1-Q4. [Full Text].

  10. Centers for Disease Control and Prevention. Recommended Immunization Schedules for Persons Aged 0--18 Years ---United States, 2008. MMWR. 2007;56(51&52):Q1-Q4.

  11. Centers for Disease Control and Prevention. Vaccine preventable deaths and the Global Immunization Vision and Strategy, 2006-2015. MMWR Morb Mortal Wkly Rep. May 12 2006;55(18):511-5. [Medline][Full Text].

  12. Geier DA, Geier MR. An evaluation of serious neurological disorders following immunization: a comparison of whole-cell pertussis and acellular pertussis vaccines. Brain Dev. Aug 2004;26(5):296-300. [Medline].

  13. He Q, Viljanen MK, Arvilommi H, et al. Whooping cough caused by Bordetella pertussis and Bordetella parapertussis in an immunized population. JAMA. Aug 19 1998;280(7):635-7. [Medline].

  14. Nennig ME, Shinefield HR, Edwards KM, et al. Prevalence and incidence of adult pertussis in an urban population. JAMA. Jun 5 1996;275(21):1672-4. [Medline].

  15. Roush SW, Murphy TV,. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA. Nov 14 2007;298(18):2155-63. [Medline].

  16. Tindberg Y, Blennow M, Granstrom M. A ten year follow-up after immunization with a two component acellular pertussis vaccine. Pediatr Infect Dis J. Apr 1999;18(4):361-5. [Medline].

  17. Ward JI, Cherry JD, Chang SJ, Partridge S, Lee H, Treanor J. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med. Oct 13 2005;353(15):1555-63. [Medline].

  18. Wright SW, Edwards KM, Decker MD, Lamberth MM. Pertussis seroprevalence in emergency department staff. Ann Emerg Med. Sep 1994;24(3):413-7. [Medline].

  19. Wright SW, Edwards KM, Decker MD, Zeldin MH. Pertussis infection in adults with persistent cough. JAMA. Apr 5 1995;273(13):1044-6. [Medline].

Keywords

whooping cough, pertussisBordetella pertussis, B pertussis, pertussis vaccination, acellular vaccination, whole-cell vaccination, protracted cough, vaccine-preventable disease, cough in infants, whole-cell vaccine, acellular vaccine, DTaP, Tdap, Td booster, immunization schedule, vaccines

Contributor Information and Disclosures

Author

Joseph J Bocka, MD, Director of Shelby Emergency Department, Attending Emergency Physician at Mansfield Hospital, Med Central Health System (Mansfield and Shelby, Ohio); Emergency Medical Service Medical Director for several services
Joseph J Bocka, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, National Association of EMS Physicians, and Phi Beta Kappa
Disclosure: Nothing to disclose.

Medical Editor

Garry Wilkes, MBBS, FACEM, Director of Emergency Medicine, Bunbury Health Service, Western Australia Country Health Service; Adjunct Associate Professor, School of Exercise, Biomedical and Health Sciences, Faculty of Computing, Health and Science, Edith Cowan University; Medical Director, St John Ambulance Service
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

Grace M Young, MD, Associate Professor, Department of Pediatrics, University of Maryland Medical Center
Grace M Young, MD is a member of the following medical societies: American Academy of Pediatrics and American College of Emergency Physicians
Disclosure: Nothing to disclose.

CME Editor

John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center
John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Chief Editor

Richard G Bachur, MD, Associate Professor of Pediatrics, Harvard Medical School; Associate Chief and Fellowship Director, Attending Physician, Division of Emergency Medicine, Children's Hospital of Boston
Richard G Bachur, MD is a member of the following medical societies: American Academy of Pediatrics, Society for Academic Emergency Medicine, and Society for Pediatric Research
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.